Moscow: Russia has said that it is all set to register the world’s first Covid19 vaccine on Wednesday before going on for the mass vaccination from October onwards. Several international bodies including the WHO have raised safety concerns but that has not deterred the country’s determination to register the vaccine.
The Sputnik news agency reported that Russian Deputy Health Minister Oleg Gridnev has revealed the complete preparedness for registering the Covid19 vaccine on August 12. The country is the fourth worst hit nation from Covid19 after US, Brazil, and India. The vaccine has been reportedly been developed by the Gamaleya Research Institute and the Russian Defence Ministry.
As per the Russian Defence Ministry, the country conduced a final medical examination of vaccine participants in clinical trials on August 3 at the Burdenko Main Military Clinical Hospital. The results showed that all volunteers had clear immune response resulting from the vaccination. There were no side effects or abnormalities.
As per the statement by the Russian Defence Ministry, “Thus, the available data of laboratory and instrumental studies allow us to speak about the safety and good tolerance of the vaccine.”
However, the Russian vaccine does not fall under the list of six vaccines that have reached the Phase 3 as per the World Health Organization. Reacting on the safety and health concerns of the Russian vaccine and whether any vaccine hits the market in this year, Michael Ryan, the Executive Director of WHO Health Emergencies Programme said, “we will still have to remain cautious”.
“Should we find that signal we should be able to move into production of that vaccine and begin to use it in human populations, but we will still have to remain cautious as we scale up the number of people vaccinated,” Ryan said to the press.
“Side effects are rare, and they only become apparent when you vaccinate lots and lots of people. So there will still be a need for a monitoring phase even when we start to vaccinate at population level,” he added.
Of the six vaccines that have reached the critical final stage, three vaccines are from China while the other three are developed by University of Oxford and AstraZeneca, Moderna, and one jointly developed by Pfizer and BioNTech.
“Phase three doesn’t mean nearly there. Phase three means this is the first time that this vaccine is being put into the general population, into otherwise healthy individuals, to see if the vaccine will protect them against natural infection,” Ryan said in the press briefing.
“In fact, it’s the beginning. Up to now all of the studies have been around safety, immunogenicity, and ensuring that the vaccine generates an immune response in a small number of humans, and doesn’t generate adverse events that would prevent the vaccine moving forward into trials,” he added.